Literature DB >> 6572894

Physiological and x-ray studies of potential antisickling agents.

D J Abraham, M F Perutz, S E Phillips.   

Abstract

Several aromatic compounds have been found to inhibit the gelling of sickle cell hemoglobin. We have tried to correlate the antigelling activity of such compounds with the stereo-chemistry of their binding sites in the hemoglobin molecule. This approach led to the discovery that two known antilipoproteinemia drugs, clofibrate and gemfibrozil, have antigelling activity. X-ray analysis showed that three pairs of molecules of clofibric acid, the active metabolite of clofibrate, bound to the walls of the internal cavity of deoxyhemoglobin A; only one pair bound to a quite different site, between helices A, E, and H of the alpha chains of carbon monoxide hemoglobin A. Unlike other antigelling agents, clofibric acid and related compounds decrease rather than increase the oxygen affinity of hemoglobin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6572894      PMCID: PMC393369          DOI: 10.1073/pnas.80.2.324

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  Experimental evaluation of an orally active combination of androsterone with ethyl chlorophenoxy-isobutyrate.

Authors:  J M THROP
Journal:  Lancet       Date:  1962-06-23       Impact factor: 79.321

2.  The effect of organic compounds on the crystal habit and crystallization of normal and sickle cell hemoglobin in phosphate buffer.

Authors:  K J Farnell; T L McMeekin
Journal:  Arch Biochem Biophys       Date:  1973-10       Impact factor: 4.013

3.  Binding of 2,3-diphosphoglycerate and adenosine triphosphate to human haemoglobin A.

Authors:  L Garby; G Gerber; C H De Verdier
Journal:  Eur J Biochem       Date:  1969-08

4.  Characterization of the interaction of the aromatic hydrocarbons benzene and toluene with human hemoglobin.

Authors:  R F Novak; M Dershwitz; F C Novak
Journal:  Mol Pharmacol       Date:  1979-11       Impact factor: 4.436

5.  Requirement for therapeutic inhibition of sickle haemoglobin gelation.

Authors:  H R Sunshine; J Hofrichter; W A Eaton
Journal:  Nature       Date:  1978-09-21       Impact factor: 49.962

6.  Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (third of three parts).

Authors:  J Dean; A N Schechter
Journal:  N Engl J Med       Date:  1978-10-19       Impact factor: 91.245

7.  The structure of human carbonmonoxy haemoglobin at 2.7 A resolution.

Authors:  J M Baldwin
Journal:  J Mol Biol       Date:  1980-01-15       Impact factor: 5.469

8.  Design, synthesis, and testing of potential antisickling agents. 1. Halogenated benzyloxy and phenoxy acids.

Authors:  D J Abraham; A S Mehanna; F L Williams
Journal:  J Med Chem       Date:  1982-09       Impact factor: 7.446

9.  Quantitative assessment of the noncovalent inhibition of sickle hemoglobin gelation by phenyl derivatives and other known agents.

Authors:  M J Behe; W S Englander
Journal:  Biochemistry       Date:  1979-09-18       Impact factor: 3.162

10.  Antisickling activity of amino acid benzyl esters.

Authors:  M Gorecki; C T Acquaye; M Wilchek; J R Votano; A Rich
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

View more
  12 in total

1.  High-resolution crystal structure of deoxy hemoglobin complexed with a potent allosteric effector.

Authors:  M K Safo; C M Moure; J C Burnett; G S Joshi; D J Abraham
Journal:  Protein Sci       Date:  2001-05       Impact factor: 6.725

2.  Oxidative effects of gemfibrozil on anion influx and metabolism in normal and Beta-thalassemic erythrocytes: physiological implications.

Authors:  Ester Tellone; Silvana Ficarra; Bruno Giardina; Roberto Scatena; Annamaria Russo; M Elisabetta Clementi; Francesco Misiti; Ersilia Bellocco; Antonio Galtieri
Journal:  J Membr Biol       Date:  2008-09-29       Impact factor: 1.843

3.  Preservation of canine myocardial high-energy phosphates during low-flow ischemia with modification of hemoglobin-oxygen affinity.

Authors:  R G Weiss; M A Mejia; D A Kass; A F DiPaula; L C Becker; G Gerstenblith; V P Chacko
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

Review 4.  Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property.

Authors:  Piyusha P Pagare; Aref Rastegar; Osheiza Abdulmalik; Abdelsattar M Omar; Yan Zhang; Andrew Fleischman; Martin K Safo
Journal:  Expert Opin Ther Pat       Date:  2021-11-01       Impact factor: 6.714

Review 5.  Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.

Authors:  Martin K Safo; Gregory J Kato
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-21       Impact factor: 3.722

6.  Photoaffinity labelling of cyanomethaemoglobin with derivatives of tryptophan and 5-bromotryptophan.

Authors:  M Li; Z Lin; M E Johnson
Journal:  Biochem J       Date:  1995-05-15       Impact factor: 3.857

7.  Effects of gemfibrozil on the oxygen transport properties of erythrocytes.

Authors:  R Scatena; G Nocca; I Messana; P De Sole; S Baroni; C Zuppi; M Castagnola; B Giardina
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

8.  Potential use of biaromatic L-phenylalanyl derivatives as therapeutic agents in the treatment of sickle cell disease.

Authors:  J R Votano; J Altman; M Wilchek; M Gorecki; A Rich
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

9.  Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.

Authors:  Eric R Henry; Belhu Metaferia; Quan Li; Julia Harper; Robert B Best; Kristen E Glass; Troy Cellmer; Emily B Dunkelberger; Anna Conrey; Swee Lay Thein; H Franklin Bunn; William A Eaton
Journal:  Blood       Date:  2021-09-30       Impact factor: 25.476

10.  Aryloxyalkanoic Acids as Non-Covalent Modifiers of the Allosteric Properties of Hemoglobin.

Authors:  Abdelsattar M Omar; Mona A Mahran; Mohini S Ghatge; Faida H A Bamane; Mostafa H Ahmed; Moustafa E El-Araby; Osheiza Abdulmalik; Martin K Safo
Journal:  Molecules       Date:  2016-08-13       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.